Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

Inclusion Criteria: * Written informed consent from parent/guardian before any study-specific procedures are performed, if applicable per local regulations. * Age-appropriate assent or informed consent from subject before any study-specific procedures are performed. * Subjects who have completed 24 weeks of treatment with study drug (voclosporin/placebo) in the VOCAL study. Subjects who had a temporary interruption and were able to successfully re-start study drug will be allowed to enroll after Medical Monitor approval. * In the opinion of the Investigator subject requires continued immunosuppressive therapy. * Subject is willing to continue to take oral MMF for the duration of the study. Exclusion Criteria: * Currently taking or known need for any of the following medications during the study: * Cholestyramine or other drugs that may interfere with enterohepatic recirculation of MMF * Calcineurin inhibitors (CNIs) (e.g., cyclosporin and tacrolimus) * Strong CYP3A4/5 inhibitors and inducers (e.g., ketoconazole, rifampin, itraconazole, clarithromycin) * Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period. * A planned kidney transplant within study treatment period. * Subjects with any medical condition which in the Investigator's judgement may be associated with increased risk to the subject or may interfere with study assessments or outcomes